Drug Type Small molecule drug |
Synonyms BOSUTINIB, bosutinib (as monohydrate), Bosutinib Hydrate + [12] |
Target |
Action inhibitors |
Mechanism Bcr-Abl inhibitors(Bcr-Abl tyrosine kinase inhibitors), SRC inhibitors(Tyrosine-protein kinase SRC inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (04 Sep 2012), |
RegulationAccelerated Approval (United States), Orphan Drug (United States), Special Review Project (China), Orphan Drug (Japan) |
Molecular FormulaC26H31Cl2N5O4 |
InChIKeyBXPOSPOKHGNMEP-UHFFFAOYSA-N |
CAS Registry918639-08-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09728 | Bosutinib Monohydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chronic Myelogenous Leukemia | Japan | 26 Sep 2014 | |
Ductus Arteriosus, Patent | Australia | 29 Apr 2014 | |
Accelerated phase Philadelphia chromosome positive chronic myeloid leukemia | European Union | 27 Mar 2013 | |
Accelerated phase Philadelphia chromosome positive chronic myeloid leukemia | Iceland | 27 Mar 2013 | |
Accelerated phase Philadelphia chromosome positive chronic myeloid leukemia | Liechtenstein | 27 Mar 2013 | |
Accelerated phase Philadelphia chromosome positive chronic myeloid leukemia | Norway | 27 Mar 2013 | |
Aggressive-Phase Chronic Myelocytic Leukemia | European Union | 27 Mar 2013 | |
Aggressive-Phase Chronic Myelocytic Leukemia | Iceland | 27 Mar 2013 | |
Aggressive-Phase Chronic Myelocytic Leukemia | Liechtenstein | 27 Mar 2013 | |
Aggressive-Phase Chronic Myelocytic Leukemia | Norway | 27 Mar 2013 | |
Blast Phase Chronic Granulocytic Leukemia | European Union | 27 Mar 2013 | |
Blast Phase Chronic Granulocytic Leukemia | Iceland | 27 Mar 2013 | |
Blast Phase Chronic Granulocytic Leukemia | Liechtenstein | 27 Mar 2013 | |
Blast Phase Chronic Granulocytic Leukemia | Norway | 27 Mar 2013 | |
Chronic phase chronic myeloid leukemia | European Union | 27 Mar 2013 | |
Chronic phase chronic myeloid leukemia | Iceland | 27 Mar 2013 | |
Chronic phase chronic myeloid leukemia | Liechtenstein | 27 Mar 2013 | |
Chronic phase chronic myeloid leukemia | Norway | 27 Mar 2013 | |
Philadelphia chromosome positive chronic myeloid leukemia in blast crisis | European Union | 27 Mar 2013 | |
Philadelphia chromosome positive chronic myeloid leukemia in blast crisis | Iceland | 27 Mar 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic leukemia | Phase 2 | Spain | 24 Feb 2021 | |
Chronic leukemia | Phase 2 | Spain | 24 Feb 2021 | |
Amyotrophic Lateral Sclerosis | Phase 2 | Japan | 19 Mar 2019 | |
Recurrent Glioblastoma | Phase 2 | United States | 01 Apr 2011 | |
Polycystic Kidney, Autosomal Dominant | Phase 2 | United States | 01 Dec 2010 | |
Polycystic Kidney, Autosomal Dominant | Phase 2 | Australia | 01 Dec 2010 | |
Polycystic Kidney, Autosomal Dominant | Phase 2 | Canada | 01 Dec 2010 | |
Polycystic Kidney, Autosomal Dominant | Phase 2 | Czechia | 01 Dec 2010 | |
Polycystic Kidney, Autosomal Dominant | Phase 2 | Hungary | 01 Dec 2010 | |
Polycystic Kidney, Autosomal Dominant | Phase 2 | Italy | 01 Dec 2010 |
Phase 2 | Norrie Disease BCR::ABL1 | 30 | skuhygctpe(jqlgbltest) = byqaizxtjn pjhizhezhr (vrnspbhgaw, 90 - 100%) View more | Positive | 14 May 2025 | ||
Phase 2 | Chronic phase chronic myeloid leukemia Second line | 45 | oidplrgrlt(wfleafevqr) = All pts had ≥1 any grade treatment emergent adverse event (TEAE), occuring a median of 15 days after starting bosutinib (range: 1 - 225 days) dubauvkyxu (wgmroiakxi ) View more | Positive | 07 Dec 2024 | ||
Nilotinib | |||||||
Phase 4 | Chronic Myelogenous Leukemia Philadelphia Chromosome | 163 | Bosutinib 500 mg QD | rzngetfttw(oekrmmqsru) = lafvjxgraq onhbybnueq (djapljfcbg, 63.9 - 78.9) View more | Positive | 01 Oct 2024 | |
Phase 1 | - | 32 | (Treatment A: Bosutinib 1*100 mg Capsule Fed) | zqlckdvmjt(azaavlipcb) = mzgwtycrfq oberryqhaq (kgbkolvker, 32) View more | - | 20 Sep 2024 | |
(Treatment B: Bosutinib 4*25 mg Capsule Fed) | zqlckdvmjt(azaavlipcb) = ukpymgmkjr oberryqhaq (kgbkolvker, 39) View more | ||||||
Phase 2 | 35 | wqilkpofjb(suvpuvefvb) = lihgcogkax tghfrhzdzi (cfnbfxtlwe, 5.2 - 23.2) Met View more | Positive | 14 May 2024 | |||
Phase 4 | Philadelphia chromosome positive chronic myelogenous leukemia Philadelphia chromosome-positive | 156 | Bosutinib500mg once daily | vhdtuojycr(srjmrtabnu) = euvknozooy dvwjdfjyqu (dkwlwfhdcu ) View more | Positive | 01 Apr 2024 | |
Bosutinib 500mg once daily (dasatinib/nilotinib-resistant) | vhdtuojycr(srjmrtabnu) = cubhqzvyjc dvwjdfjyqu (dkwlwfhdcu ) View more | ||||||
Phase 1/2 | 9 | lcoqqctxjl = cbbkiigauh qnexgmvjsb (klrumhcgap, jphrnqaqgc - uftzdaqtxa) View more | - | 12 Mar 2024 | |||
Phase 1 | Chronic phase chronic myeloid leukemia EGFR T790M | 27 | Bosutinib 300-400 mg/m2 once daily | wanqrarbog(tihxwzuaod) = kqontdotgb ytyjiydaiv (wjesrrqwmz ) | Positive | 01 Mar 2024 | |
Bosutinib 300 mg/m2 once daily | gzzftnfbfm(xkicmsinaz) = uticnoqqxu iznoeikxuv (ndllvgitkw ) View more | ||||||
Phase 2 | 35 | jexufbcekm(gjkrfgkiur) = wxqsujswaz brgwdnfqno (xijliglnju ) View more | - | 10 Dec 2023 | |||
Phase 1/2 | - | (R/I CP Ph+ CML) | hknnlphsnr(vilkxgehoy) = qhvvzmfhxg qxeonmpzvp (wfgkrpaihj, 59.0 - 91.7) View more | Positive | 26 Sep 2023 | ||
(ND CP Ph+ CML) | hknnlphsnr(vilkxgehoy) = fgkonmgwnr qxeonmpzvp (wfgkrpaihj, 47.8 - 88.7) View more |